# Bionano Genomics, Inc. (BNGO)

> Source: Nexqual · https://nexqual.com/BNGO · data as of 2026-10-23 16:44 UTC · cite as "Nexqual, Bionano Genomics, Inc. (BNGO), nexqual.com/BNGO" · informational, not investment advice.

**Price:** USD 1.13 (-4.25% today) · US market open, as of October 23, 2026 at 16:44 UTC; quotes may be delayed. Prev close 1.18 · day 1.1–1.18 · 52w 1–2.23 · market cap $13.3M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $30.2M, net income -$32.2M (-106.6% margin) (SEC filings).
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $10K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -40.8% vs S&P 500 +14.6%; 5Y -100.0% vs S&P 500 +77.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.45, revenue estimate $8.4M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $18.0M | $27.8M | $36.1M | $30.8M | $28.5M | $30.2M |
| Gross profit | $3.9M | $5.9M | $9.6M | $380K | $13.2M | — |
| Operating income | -$77.1M | -$132M | -$215M | -$104M | -$33.3M | -$32.2M |
| Net income | -$72.4M | -$133M | -$232M | -$112M | -$26.4M | -$32.2M |
| EPS (diluted) | -$156.00 | -$274.80 | -$408.60 | -$88.13 | -$4.85 | — |
| Gross margin | 21.5% | 21.4% | 26.5% | 1.2% | 46.3% | — |
| Operating margin | -428.8% | -473.7% | -596.0% | -337.9% | -116.9% | -106.7% |
| Net margin | -402.8% | -476.9% | -643.7% | -364.0% | -92.6% | -106.6% |
| Revenue growth | +111.5% | +54.6% | +29.9% | -14.8% | -7.4% | — |
| Cash + short-term investments | $251M | $113M | $66.8M | $9.5M | $19.3M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 0.4x · P/B 0.4x · Earnings yield -241.70%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
2 purchases, $10K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-04 | Luderer Albert | Interim Chief Executive | 4,000 | $5K | 1.21 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-21 | Luderer Albert | Interim Chief Executive | 4,000 | $5K | 1.22 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -40.8% | -100.0% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -40.9% | -79.4% |
| Volatility (annualized) | 61.2% | 97.7% |
| Max drawdown | -45.1% (Oct 2025→Jul 2026) | -100.0% (Nov 2021→Jul 2026) |

## Peers (Medical Instruments & Supplies)
KMTS (Kestra Medical Technologies, Lt) USD 28.48 +0.56% · XRAY (DENTSPLY SIRONA Inc.) USD 9.43 -0.74% · LMAT (LeMaitre Vascular, Inc.) USD 84.52 -0.95% · ATRC (AtriCure, Inc.) USD 58.83 -0.79% · WRBY (Warby Parker Inc.) USD 25.64 -0.12% · NVST (Envista Holdings Corporation) USD 23.76 -0.88%

## More
Full page: https://nexqual.com/BNGO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in BNGO's own 10-K filed 2026-03-23 (https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/bngo-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Cowen and Company | "In March 2021, we entered into a Sales Agreement with Cowen and Company, LLC ("Cowen") which provides for the sale, in our sole discretion, of shares of our common stock having a maximum aggregate offering price of up to…" |
| Partner | MYRIAD GENETICS INC (MYGN) | "Myriad Genetics, Inc., Mayo Collaborative Services v." |
| Partner | JGB Collateral | "On May 24, 2024, we entered into a securities purchase agreement with certain accredited investors (the "Holders") and JGB Collateral LLC, as collateral agent for the Holders, for the sale by the Company in a private pla…" |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Product | $7.7M | 94.2% | +21.9% |
| — Consumable Revenue (part of Product) | $4.3M | 52.4% | +30.8% |
| — Instrument Revenue (part of Product) | $2.0M | 24.9% | +45.6% |
| — Software Revenue (part of Product) | $1.4M | 16.8% | -16.1% |
| Product & Service Other | $478,000 | 5.8% | +13.0% |
| Total revenue | $8.2M | 100% | — |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| EMEA | $4.8M | 59.2% | +50.0% |
| Americas | $3.0M | 37.0% | +3.3% |
| Asia Pacific | $307,000 | 3.8% | -47.0% |
| Total revenue | $8.2M | 100% | — |

## Customer concentration

Period ended 2024-12-31: 10% of revenue from unnamed direct customers (10-K, filed 2026-03-23).

## Company outlook (8-K filed 2026-08-10)

- "We anticipate the following results for Q3 and the full year 2026: • Q3 2026 revenue guidance in the range of $8.2 to $8.6 million. • Full year 2026 revenue guidance in the range of $31 to $33 million."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.45 | $-0.54 | -16.7% | $8.4M | 1 |
| Next quarter (ends 2026-12-31) | $-0.39 | $-0.51 | -23.5% | $9.3M | 1 |
| Current fiscal year (ends 2026-12-31) | $-2.14 | $-2.71 | -21.0% | $32.1M | 1 |
| Next fiscal year (ends 2027-12-31) | $-0.97 | $-1.11 | -12.6% | $43.3M | 1 |